Global Hemophilia Market Report 2022-2026, By Treatment Regimen, Type & Therapy – – QNT Press Release


The “Global Hemophilia Market (By Treatment Regimen, Type & Therapy): Insights & Forecast with Potential Impact of COVID-19 (2022-2026)” report has been added to’s offering.

The global hemophilia market is anticipated to reach US$15.86 billion in 2026, growing at a CAGR of 5.82% during the period spanning 2022-2026.

The growth in the market has been driven by factors like increasing healthcare expenditure, surging identified hemophilia patient volume, increased focus on prophylactic treatment, rise in male population and favorable government initiatives. The market is expected to face certain challenges such as high cost of treatment and reluctance to switch to newer therapies. To overcome these challenges, the market would witness some key trends like development of novel hemophilia treatments and rising popularity of gene therapy.

The global hemophilia market by treatment regimen can be segmented as follows: prophylaxis and on-demand. In 2021, the higher share was held by prophylaxis segment, followed by on-demand segment. The global hemophilia market by type can be segmented into the following : hemophilia A and hemophilia B, where hemophilia A held a larger share of the market in 2021. The global hemophilia market by therapy can be segmented as follows: replacement therapy and ITI therapy. The dominant share of the market in 2021 was held by replacement therapy segment.

Full story available on


Source link

Recommended For You

About the Author: News Center